Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indrayani BiotechBOM:526445 50 Receivables Turnover is 0.56 as of Dec. 2025. GuruFocus rates BOM:526445 with a GF Score™ of 50/100 and a GF Value™ of ₹41.79 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,062 Business Services companies, Indrayani Biotech ranks worse than 87.48% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Indrayani Biotech's Revenue for the
three
months ended in Dec. 2025 was ₹350 Mil. Indrayani Biotech's average Accounts Receivable for the
three
months ended in Dec. 2025 was ₹623 Mil.
Hence, Indrayani Biotech's Receivables Turnover for the
three
months ended in Dec. 2025 was 0.56.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Indrayani Biotech Receivables Turnover Related Terms
Indrayani Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Indrayani Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:526445 vs CTAS, CPRT, GPN: Receivables Turnover Comparison
For the Specialty Business Services subindustry, Indrayani Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indrayani Biotech Receivables Turnover vs Business Services Industry
For the Business Services industry and Industrials sector, Indrayani Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Indrayani Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indrayani Biotech (BOM:526445) has a Receivables Turnover of 0.56 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Indrayani Biotech and its competitors. According to the industry distribution chart, Indrayani Biotech ranks #929 out of 1062 companies in the Business Services industry, placing it in the top 87.5%.
Is Indrayani Biotech's Receivables Turnover too high?
Indrayani Biotech's current Receivables Turnover is 0.56. The Business Services industry median Receivables Turnover is 6.39. Indrayani Biotech's value of 0.56 is 91.2% below this industry median. Based on the distribution chart, Indrayani Biotech ranks #929 out of 1062 companies in the Business Services industry, which is in the bottom quartile relative to peers. Overall, Indrayani Biotech has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indrayani Biotech's Receivables Turnover compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Indrayani Biotech ranks #929 out of 1062 companies for Receivables Turnover. This places Indrayani Biotech in the lower half of its industry. The industry median Receivables Turnover is 6.39. Indrayani Biotech's value of 0.56 is 91.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Business Services company?
The median Receivables Turnover among Business Services companies is 6.39, based on 1,062 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indrayani Biotech's current Receivables Turnover of 0.56 is 91.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Indrayani Biotech and its competitors. For the Business Services industry, the median Receivables Turnover is 6.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indrayani Biotech's current Receivables Turnover is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indrayani Biotech stock overvalued right now?
Based on GuruFocus' analysis, Indrayani Biotech (BOM:526445) is currently considered Possible Value Trap. The stock's GF Value™ is ₹41.79, compared to a current price of ₹7.80 — trading 81.3% below its estimated fair value. The current Receivables Turnover is 0.56 and 91.2% below the Business Services industry median of 6.39. Indrayani Biotech's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Indrayani Biotech (BOM:526445), the current Receivables Turnover is 0.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indrayani Biotech (BOM:526445) Overvalued in 2026?
Based on GuruFocus' analysis, Indrayani Biotech stock appears to be undervalued.
The current stock price of ₹7.80 is trading 81.3% below its estimated GF Value™ of ₹41.79.
GuruFocus considers Indrayani Biotech to be Possible Value Trap.
Key valuation signals for BOM:526445:
Receivables Turnover: 0.56
GF Value™: ₹41.79 vs. price of ₹7.80 (81.3% below fair value)
Industry Position: 91.2% below the Business Services median (#929 of 1062)
No single metric tells the full story. See the BOM:526445 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indrayani Biotech Ltd operates in the Tri-segment i.e. Foods & Hospitality, Engineering and Healthcare divisions. The company generates its revenue from the sale of food, beverages, and other items; the Sale of Engineering products & Others. The majority of its revenue is generated from the sale of food, beverages, and other items.
50GF Score
Get the complete analysis for BOM:526445
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526445 has been successfully added to your 
